Brief ReportBrief Report

Quantifying Worsened Glycemic Control During the COVID-19 Pandemic

C. J. W. Ledford, C. Roberts, E. Whisenant, C. Walters, K. Akamiro, J. Butler, A. Ali and D. A. Seehusen
The Journal of the American Board of Family Medicine February 2021, 34 (Supplement) S192-S195; DOI: https://doi.org/10.3122/jabfm.2021.S1.200446

Article Figures & Data

Tables

  • Table 1.

    Demographic Variables and HbA1c Results for May 2019 and May 2020 Patients

    2019 (n = 156)2020 (n = 144)p-Value
    Age (mean, SD)61.0 (11.7)60.4 (13.4)NS
    Women (%)111 (71.2)89 (61.8)NS
    White (%)53 (34.0)45 (31.1)NS
    Insurance status (%)NS
     Medicaid85 (54.5)68 (47.2)
     Medicare14 (9.0)22 (15.3)
     Insurance52 (33.3)47 (32.6)
     Self-pay5 (3.2)7 (4.9)
    Antidiabetic medication (%)NS
     None25 (16.0)32 (22.2)
     Only noninsulin medications87 (55.8)66 (45.8)
     Insulin44 (28.2)46 (31.9)
    Median household income (mean, SD)$38,529 (15,732)$40,399 (13,707)NS
    Baseline HbA1c (mean, SD)7.65 (1.50)7.61(1.71)NS
    May HbA1c (mean, SD)7.19 (1.45)7.63 (1.73)<0.01

    • SD, standard deviation.

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords